Global Oncolytic Virus Cancer Immunotherapy Market Growth (Status and Outlook) 2025-2031

According to this study, the global Oncolytic Virus Cancer Immunotherapy market size will reach US$ million by 2031.

Oncolytic virus is a special virus that can beneficially infect and kill cancer cells. These are deployed as part of cancer immunotherapy and work by selectively targeting cancer cells and performing oncolytics. Oncolytic viruses can not only kill cancer cells directly, but also stimulate patients" own anti-tumor immune response.

The first oncolytic virus immunotherapy was approved in Latvia in 2004 for the treatment of cutaneous melanoma. Inevitable changes in the environment due to human activities are causing various factors, leading to an increase in the incidence of many skin malignancies, including non-melanoma skin cancer. Conventional radiation and chemotherapy known to treat various cancers, including cutaneous melanoma, have a limited therapeutic index and a range of treatment-related side effects.

LPI (LP Information)' newest research report, the “Oncolytic Virus Cancer Immunotherapy Industry Forecast” looks at past sales and reviews total world Oncolytic Virus Cancer Immunotherapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Oncolytic Virus Cancer Immunotherapy sales for 2025 through 2031. With Oncolytic Virus Cancer Immunotherapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oncolytic Virus Cancer Immunotherapy industry.

This Insight Report provides a comprehensive analysis of the global Oncolytic Virus Cancer Immunotherapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oncolytic Virus Cancer Immunotherapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oncolytic Virus Cancer Immunotherapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oncolytic Virus Cancer Immunotherapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oncolytic Virus Cancer Immunotherapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Oncolytic Virus Cancer Immunotherapy market by product type, application, key players and key regions and countries.

Segmentation by Type:
Monoclonal Antibodies
Checkpoint Inhibitors
Oncoloytic Viral Therapies and Cancer Vaccines

Segmentation by Application:
Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and neck Cancer
Ovarian Cancer
Pancreatic Cancer
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Amgen
F Hoffman-La Roche
Bristol-Myers Squibb
Novartis AG
Merck & Co., Inc.
Pfizer
Biovex
Cell Genesys
Crusade Laboratories
Genelux Corporation
Lokon Pharma
MultiVir

Please note: The report will take approximately 2 business days to prepare and deliver. Show more